SILO
Silo Pharma, Inc. NASDAQ$0.45
Mkt Cap $3.6M
52w Low $0.22
25.3% of range
52w High $1.13
50d MA $0.40
200d MA $0.49
P/E (TTM)
-0.9x
EV/EBITDA
0.4x
P/B
0.6x
Debt/Equity
0.0x
ROE
-67.0%
P/FCF
-0.6x
RSI (14)
—
ATR (14)
—
Beta
0.59
50d MA
$0.40
200d MA
$0.49
Avg Volume
5.0M
About
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | — | -0.07 | — | 0.34 | -2.1% | +0.8% | +5.8% | +1.1% | +1.6% | +4.6% | — |
| Nov 13, 2025 | AMC | — | -0.12 | — | 0.44 | -1.2% | -5.1% | -6.1% | -3.7% | -9.3% | -16.5% | — |
| Aug 13, 2025 | AMC | — | -0.19 | — | 0.70 | -1.5% | -1.2% | +1.3% | +0.8% | -5.8% | -7.2% | — |
| May 9, 2025 | AMC | — | -0.23 | — | 0.81 | +15.7% | +31.3% | +35.0% | +2.6% | -36.2% | -40.7% | — |
| Mar 28, 2025 | AMC | — | -0.41 | — | 1.25 | -2.4% | -6.4% | -9.6% | -13.6% | -11.2% | -13.6% | — |
| Nov 12, 2024 | AMC | — | -0.22 | — | 1.23 | -1.6% | -10.6% | -6.5% | -8.1% | -19.5% | -21.1% | — |
| Aug 13, 2024 | AMC | — | -0.31 | — | 1.25 | -2.4% | +9.6% | +8.8% | +19.2% | +16.0% | +12.8% | — |
| May 13, 2024 | AMC | — | -0.28 | — | 1.77 | -1.7% | +2.3% | +2.3% | +6.2% | +13.6% | +14.7% | — |
| Mar 25, 2024 | AMC | -0.20 | -0.36 | -80.0% | 1.93 | -1.0% | +0.5% | -1.0% | +1.0% | -1.6% | +1.0% | — |
| Nov 13, 2023 | AMC | -0.21 | -0.21 | +0.0% | 1.34 | -2.6% | -3.3% | -1.0% | +10.8% | +17.9% | +21.1% | — |
Recent Filings
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
SILO signed a material agreement with Many Ads Inc., suggesting potential revenue diversification or advertising partnership that could improve margins and investor returns if executed successfully.
Apr 2
8-K · 8.01
!! High
Silo Pharma, Inc. -- 8-K 8.01: Material Event / Announcement
Silo Pharma's board approved a $1 million stock repurchase program, signaling management confidence in the stock's value while potentially supporting the share price.
Feb 23
Data updated apr 27, 2026 1:20am
· Source: massive.com